Should the infrastructure bill be enacted, with “Aspects of H.R. 3” that include measures which peg U.S. prices of a number of prescription drugs to an international price index, it may have negative ramifications for the biopharmaceutical industry.
The direct price control measures in H.R. 3 go further and are of more immediate consequence to the biopharmaceutical industry.
It’s difficult to predict the precise series of responses by the biopharmaceutical industry to drug price containment actions subsumed under the pending infrastructure bill.
Read full article here